- Genentech has increased its investment in a new manufacturing facility in Holly Springs, North Carolina, to approximately $2 billion, more than doubling its original commitment.
- The site is expected to be operational by 2029, support more than 500 manufacturing jobs, and produce treatments for metabolic conditions.
Genentech, a member of the Roche Group, has expanded its investment in a new manufacturing facility in Holly Springs, North Carolina, increasing the total commitment to around $2 billion. The move builds on an initial investment announced in May 2025 and follows the project’s groundbreaking in August 2025.
The expanded project will add production capacity and increase output at what will be the company’s first manufacturing facility on the U.S. East Coast. Once operational in 2029, the site will manufacture next-generation treatments for metabolic conditions, including obesity. The facility will use advanced biomanufacturing approaches, automation and digital tools to improve efficiency and strengthen the company’s U.S.-based supply chain.
The investment is expected to create an additional 100 jobs in North Carolina, bringing total employment supported by the project to more than 500 manufacturing roles. The company stated that the expansion is intended to support long-term domestic production capacity.
The Holly Springs expansion forms part of a broader $50 billion commitment by Roche and Genentech to manufacturing in the United States and aligns with efforts to strengthen domestic production and innovation. The companies currently operate 13 manufacturing and 15 R&D sites across their Pharmaceutical and Diagnostics divisions in the U.S., employing around 25,000 people across 24 sites in eight states.
“We are excited to further expand our investment in our state-of-the-art manufacturing facility in Holly Springs. This expansion reflects our long-term commitment to the U.S. and communities like Holly Springs that offer the kind of world-class biotech talent, top research institutions, and strong infrastructure that make innovation possible.”
Genentech CEO Ashley Magargee
